Corti S, Locatelli F, Strazzer S, Guglieri M, Comi G P
Centro Dino Ferrari, Dipartimento di Scienze Neurologiche, Universita degli Studi di Milano, I.R.C.C.S. Ospedale Maggiore Policlinico, Centro di Eccellenza per lo Studio delle Malattie Neurodegenerative, Milano, Italy.
Curr Gene Ther. 2003 Jun;3(3):247-72. doi: 10.2174/1566523034578375.
Stem cell transplantation through cell replacement or as vector for gene delivery is a potential strategy for the treatment of neurodegenerative diseases. Several studies have reported the transdifferentiation of different somatic stem cells into neurons in vitro or after transplantation into animal models. This observation has pointed out the perspective of using an ethical and accessible cell source to "replace" damaged neurons or provide support to brain tissue. However, recent findings such as the cell fusion phenomenon have raised some doubts about the real existence of somatic stem cell plasticity. In this review, we will discuss current evidence and controversial issues about the neuroneogenesis from various sources of somatic cells focusing on the techniques of isolation, expansion in vitro as well as the inductive factors that lead to transdifferentiation in order to identify the factors peculiar to this process. The morphological, immunochemical, and physiological criteria to correctly judge whether the neuronal transdifferentation occurred are critically presented. We will also discuss the transplantation experiments that were done in view of a possible clinical therapeutic application. Animal models of stroke, spinal cord and brain trauma have improved with Mesenchymal Stem Cells or Bone Marrow transplantation. This improvement does not seem to depend on the replacement of the lost neurons but may be due to increased expression levels of neurotrophic factors, thus suggesting a beneficial effect of somatic cells regardless of transdifferentiation. Critical understanding of available data on the mechanisms governing the cell fate reprogramming is a necessary achievement toward an effective cell therapy.
通过细胞替代或作为基因递送载体进行干细胞移植是治疗神经退行性疾病的一种潜在策略。多项研究报道了不同的体干细胞在体外或移植到动物模型后可转分化为神经元。这一观察结果指出了使用符合伦理且易于获取的细胞来源来“替代”受损神经元或为脑组织提供支持的前景。然而,诸如细胞融合现象等最新发现对体干细胞可塑性的真实存在提出了一些质疑。在这篇综述中,我们将讨论关于各种体细胞来源的神经发生的现有证据和有争议的问题,重点关注分离技术、体外扩增以及导致转分化的诱导因子,以便确定这一过程特有的因素。还将批判性地介绍正确判断神经元转分化是否发生的形态学、免疫化学和生理学标准。我们还将讨论鉴于可能的临床治疗应用而进行的移植实验。间充质干细胞或骨髓移植已改善了中风、脊髓和脑外伤的动物模型。这种改善似乎并不取决于丢失神经元的替代,而可能是由于神经营养因子表达水平的提高,因此表明体细胞无论是否转分化都具有有益作用。对有关细胞命运重编程机制的现有数据进行批判性理解是实现有效细胞治疗的必要成果。